With biological production systems, reproducibility is certainly a virtue. But there is more: Process robustness! Always aim for processes that can take shocks but still give you what you want at the end. Less failed batches, less stress, more reliable production.

Consistency between production batches isn’t a “nice to have.” It’s a baseline requirement for building trust, managing supply chains, and scaling innovation into market-ready reality.

A product that performs once, in a single trial or production run, is a prototype, not a solution.

Inconsistent batches create risk at every level:

• Field data becomes unreliable.
• Client confidence erodes.
• Regulatory approvals become harder to defend.
• Formulation or logistics must be adjusted batch-by-batch.

In short: without reproducibility, performance cannot be trusted.

And yet, reproducibility remains one of the most overlooked challenges in microbial manufacturing.

Biological products, such as proteins and cells, are quite capricious products. Even if one follows very closely the “production recipe”, full guarantee of the end-product performance is not assured. The biological product will need to face the stress associated with product formulation and its “acceptance” by more or less hostile field conditions. Even the best medicines are not 100% efficacious.

At Proventus, reproducibility is engineered into every step of development, from early strain selection to full-scale production. Our goal is simple: every batch must perform like the last one and the next.

Our reproducibility protocol includes:

1. Industrial-scale fermentation modeling
   We anticipate the effects of scale-up from day one, testing at multiple volumes and stress levels—not just in R&D-scale conditions.
2. Process control and documentation
   Fermentation parameters are tightly monitored. Deviations are logged, analyzed, and used to refine SOPs for future runs.
3. Intermediate QA checkpoints
   We introduce quality checks at key stages—pre-harvest, post-harvest, pre-formulation—to catch deviations before they become customer-facing issues.
4. Formulation consistency safeguards
   Our formulation workflows are adapted to minimize operator variability, preserve microbial stability, and maintain homogeneity at scale.

Scaling up a microbial process where the cell is the wanted product implies risk at each scale-up step, the riskiest one being the transition from shake flasks to the first small-scale bioreactor. It may go from total failure to 100% success, 70% being quite a promising result. One needs to remain modest: We may think that we are in control of the operations but the cell decides at the end. Scale-up work teaches you humility.

In microbial B2B markets, innovation alone is not enough.

Clients want confidence:

• Confidence that today’s batch will match last quarter’s.
• Confidence that regional production can deliver identical performance.
• Confidence that long-term partnerships won’t collapse due to hidden drift.

For distributors and integrators, reproducibility means reduced risk, smoother logistics, and stronger customer retention.

Microbial innovation doesn’t scale unless quality scales with it. At Proventus, batch-to-batch reproducibility isn’t a technical milestone. It’s the foundation of trust internally, operationally, and in-market.

Because in microbial manufacturing, a product isn’t judged by its best batch.
It’s judged by its worst.